Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02372227 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
A Phase 1 study, sponsored by Verastem.
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT02372227 is a Phase 1 study that was terminated before completion, run by Verastem. The registered enrollment target is 21 participants.
The verdict
NCT02372227, a Phase 1 study, was terminated before completion, sponsored by Verastem.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate rising dose levels of VS-5584 administered in combination with a fixed dose of VS-6063 in subjects with relapsed malignant mesothelioma to determine a recommended Phase 2 dose (RP2D) for further development of this combination in this indication.
Interventions
- DRUG VS-5584 and VS-6063
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2015-01 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02372227
The ClinicalTrials.gov registry entry for NCT02372227 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Verastem, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VS-5584 and VS-6063 is the first listed.
NCT02372227 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02372227 about?
NCT02372227 is a clinical study titled "A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma". The purpose of this study is to evaluate rising dose levels of VS-5584 administered in combination with a fixed dose of VS-6063 in subjects with relapsed malignant mesothelioma to determine a recommended Phase 2 dose (RP2D) for further development of this combination in this indication.
What is the current status of trial NCT02372227?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2015-01. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02372227?
The interventions under investigation include: VS-5584 and VS-6063 (DRUG).
Who is sponsoring clinical trial NCT02372227?
This trial is sponsored by Verastem, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.